Chi-Iou Lin

Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism.

Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells.

Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism.

Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3.

Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3.

Lysophosphatidic acid stimulates thrombomodulin lectin-like domain shedding in human endothelial cells.

Establishment of a fluorescence resonance energy transfer-based bioassay for detecting dioxin-like compounds.

Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms.

Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.

Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer.

Autophagy: a new target for advanced papillary thyroid cancer therapy.

Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.

Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer.

Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.

Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers.

Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.

Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma.

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.